Punctal plug demonstrates proof of concept

Article

QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).

QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).

QLT Plug Delivery is a wholly-owned subsidiary of QLT, Inc.

The open label study evaluated the punctal plug, which elutes latanoprost, in five patients (10 eyes) with glaucoma or ocular hypertension. Mean IOP was measured over a 90-day period. Six eyes completed the study; two patients lost plugs, but no serious adverse events were reported.

Mean IOP at baseline was 23 mmHg; 90 days after insertion of the punctal plugs, mean IOP decreased to 17 mmHg.

Patients are now being enrolled in a Phase II randomized, double-masked trial assessing the punctal plug delivery system with low, medium and high doses of latanoprost for the treatment of glaucoma and ocular hypertension.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.